vaccine
–
–
–
6medias
Published on
–
This is a first step for the Johnson & Johnson vaccine. Friday, April 23, the American health authorities have indeed given the green light to the resumption of vaccination with the serum. Operations were suspended on April 13 after rare cases of thrombosis. “Use of Janssen’s Covid-19 vaccine is expected to resume in the United States,” the Centers for Disease Control and Prevention (CDC) and the US drug agency, the FDA, said in a statement. that the benefits of the vaccine outweighed the risks in people 18 years of age and older.
The break in the use of the vaccine developed by the American laboratory had been decided to investigate several cases of women who developed serious cases of blood clots in association with low levels of platelets after their injection. “The FDA and CDC are confident that this vaccine is safe and effective in preventing Covid-19,” the two agencies said. “For now, the available data suggests that the risk of ‘thrombosis’ is very low, but the FDA and the CDC will remain vigilant and will continue to investigate this risk,” according to the text.
An “essential step”
Health workers administering the vaccine as well as those receiving it “should review the updated” vaccine information sheet, “which has been updated to include information on the risk of this syndrome, which has emerged. produced in a very small number of people who have received the Janssen vaccine “. Earlier Friday, experts from the US health authority recommended resuming vaccination with Johnson’s serum.
>> Read also – The EMA unveils its recommendations for the Johnson & Johnson vaccine
The company’s scientific director, Paul Stoffels, said he was “grateful” for the decision of the experts, according to him “an essential step towards the continuation of the urgently needed vaccinations, in a safe environment, for millions of people. in the USA”. The Johnson & Johnson vaccine has already been given to 7.98 million people in the country. According to data presented Friday, out of 3.99 million women vaccinated, 15 developed severe cases of blood clots, and three died.
“Probable cause”
Thirteen of them were under 50 years old, the other two were between 50 and 64 years old. There have been no known cases in vaccinated men. Some experts have highlighted the benefits of this single-dose vaccine, which can be stored in refrigerators and more easily reach vulnerable groups, faced with the very rare risks of thrombosis, which can have devastating neurological consequences even when they are not fatal. .
>> Read also – Why Japan lost the vaccine match against Covid-19
“It would be detrimental to do away with a vaccine which can be administered in a single dose and which is preferred by the Hispanic community,” said Dr. Jose Romero, head of the expert committee. The J&J vaccine has been shown to be 66% effective in preventing moderate to severe forms of Covid-19, according to clinical trials conducted on approximately 40,000 people aged 18 or over in several countries around the world.
Even though the link with the vaccine has not been demonstrated, scientists consider it to be the “probable cause” of the phenomenon of thrombosis, also detected with the AstraZeneca vaccine. Johnson & Johnson and AstraZeneca technology uses an adenovirus as a vector, such as the Russian Sputnik V and Chinese CanSino vaccines.
–
